Effect of melatonin on the cardiotoxicity of doxorubicin

Histology and Histopathology

Volumn 19, Issue 4, 2004, Pages 1101-1108

  Balli, Ebru ^a   Mete, U O ^a   Tuli, A ^a   Tap, O ^a   Kaya, M ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

Cardiac muscle; Doxorubicin; Melatonin; Ultrastructure

Indexed keywords

COLLAGEN FIBRIL; DOXORUBICIN; MALONALDEHYDE; MELATONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CELL DESTRUCTION; CONTROLLED STUDY; ELECTRON MICROSCOPY; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; MALE; NONHUMAN; RAT; SARCOMERE; SARCOPLASMIC RETICULUM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; HEART; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MELATONIN; MICROSCOPY, ELECTRON; MITOCHONDRIA, HEART; MYOCARDIUM; RATS; RATS, WISTAR;

ANIMALIA; RATTUS NORVEGICUS;

EID: 6344249219     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Agapito M.T., Antolin Y,. del Brio MT., Lópes-Burillo S., Pablos M.I. and Recio J.M. (2001).Protective effect of melatonin against adriamycin toxicity in the rat. J. Pineal Res. 31, 23-30.
2. DeAtley S.M., Aksenov M.Y., Aksenova M.V., Harris B., Hadley R., Harper P.C., Carney J.M. and Butterfield D.A. (1999). Antioxidants protect against reactive oxygen species associated with adriamycin-treated cardiomyocytes. Cancer Lett. 136, 41-46.
3. Demant E.J.F. and Jensen P.K. (1983). Destruction of phospholipids and respiratory-chain activity in pig-heart submitochondrial particles induced by an adriamycin-iron complex. Eur. J. Biochem. 132, 551-556.
4. Dziegiel P., Jethon Z., Suder E., Sopel M., Rabczyfski J., Surowiak P. and Zabel M. (2002). Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat. Exp. Toxicol. Pathol. 53, 433-439.
5. Ganey P.E., Carter L.S., Mueller R.A. and Thurman RG. (1991). Doxorubicin toxicity in perfused rat heart. Circ. Res. 68, 1610-1613.
6. Jaenke R.S. (1976). Delayed and progressive myocardial lesions after adriamycin administration in the rabbit. Cancer Res. 36, 2958-2966.
7. Kang Y.J., Sun X., Chen Y. and Zhou Z. (2002). Inhibition of doxorubicin chronic toxicity in catalase-overexpressing transgenic mouse hearts. Chem. Res. Toxicol. 15, 1-6.
8. Kocak G., Erbil K.M., Ozdemir I., Aydemir S., Sunar B., Tuncel M. and Atalay S. (2003). The protective effect of melatonin on adriamycin-induced acute cardiac injury. Can. J. Cardiol. 19, 535-541.
9. Lewis W. and Gonzalez B. (1986). Anthracycline effects on actin and actin-containing thin filaments in cultured neonatal rat myocardial cells. Lab. Invest. 54, 416-423.
10. Mailer K. and Petering D.H. (1976). Inhibition of oxidative phosphorylation in tumor cells and mitochondria by daunomycin and adriamycin. Biochem. Pharmacol. 25, 2085-2089.
11. Mariano R., Gonzalez B. and Lewis W. (1986). Cardiac actin interactions with doxorubicin in vitro. Exp. Mol. Pathol. 44, 7-13.
12. Matsuhashi T., Liu X., Karbowski M., Wozniak M., Antosiewicz J. and Wakabayashi T. (1997). Role of free radicals in the mechanism of the hydrazine-induced formation of megamitochondria. Free Radic. Biol. Med. 23, 285-293.
13. Morishima I., Matsui H., Mukawa H., Kazunori H., Toki Y., Okumura K., Ito T. and Hayakawa T. (1998). Melatonin, a pineal hormone with antioxidant property, protects against adriamycin cardiomyopathy in rats. Life Sci. 63, 511-521.
14. Mortensen S.A., Olsen H.S. and Baandrup U. (1986). Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease. Br. Heart J. 55, 274-282.
15. Myers C.E., McGuire W.P., Liss R.H., Ifrim I., Grotzinger K. and Young RC. (1977). Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science. 197, 165-167.
16. Nicolay K. Fok J.J, Voorhout W., Post J.A. and Kruijff B. (1986). Cytofluorescence detection of adriamycin-mitochondria interactions in isolated, perfused rat heart. Biochim. Biophys. Acta. 887, 35-41.
17. Ohkawa H., Ohishi N. and Yagi K. (1979). Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95, 351-358.
18. Parola M., Pinzani M., Casini A., Albano E., Poli G., Gentilini A., Gentilini P, and Dianzani M.U. (1993). Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen. 1 gene expression in human liver fat-storing cells. Biochem. Biophys. Res. Commun. 194, 1044-1050.
19. Poli G. and Parola M. (1997). Oxidative damage and fibrogenesis. Free Radic. Biol. Med. 22, 287-305.
20. Pollakis G,, Goormaghtigh E, and Ruysschaert JM. (1983). Role of the quinone structure in the mitochondrial damage induced by antitumor anthracyclines.Comparison of adriamycin and 5-iminodaunorubicin. FEBS Lett. 155, 267-272.
21. Quintana D.S., Climent V., Martinez V.G., Macias D. and Hurle J.M.. (1994). Extracellular matrix arrangement in the papillary muscles of the adult rat heart. Alterations after doxorubicin administration and experimental hypertension. Basic Res. Cardiol. 89, 279-292.
22. Seraydarian M.W. and Artaza L. (1979). Modification by adenosine of the effect of adriamycin on myocardial cells in culture. Cancer Res. 39, 2940-2944.
23. Singal P.K., Deally C.M.R. and Weinberg L.E. (1987). Subcellular effects of adriamycin in the heart: A concise review. J. Mol. Cell. Cardiol. 19, 817-828.
24. Sussman M.A., Alvarez S.F.H., Vilalta P.M., Welch S. and Kedes L. (1997). Involvement of phosphorylation in doxorubicin-mediated myofibril degeneration. An immunofluorescence microscopy analysis. Circ. Res. 80, 52-61.
25. Suzuki T., Minamide S., Iwasaki T., Yamamoto H. and Kanda H. (1997). Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: Comparative study with doxorubicin. Invest. New Drugs. 15, 219-225.
26. Tong J., Ganguly P.K. and Singal P.K. (1991). Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. Am. J. Physiol. Heart Circ. Physiol. 260, H909-H916.
27. Torti F.M., Bristow M.M., Lum B.L., Carter S.K., Howes A.E., Aston D.A., Brown B.W., Hannigan J.F, Meyers F.J., Mitchell E.P. and Billingham M.E. (1986). Cardiotoxicity of epirubicin and doxorubicin:Assessment by endomyocardial biopsy. Cancer Res. 46, 3722-3727.
28. Unverferth D.V,. Jagadeesh J.M., Unverferth B.J., Magorien R.D., Leier C.V. and Balcerzak S.P. (1983). Attemt to prevent doxorubicin-induced acute human myocardial morphologic damage with acetylcysteine. J. Natl. Cancer Inst. 71, 917-920.
29. Wahab M.H.A., Akoul E.S.E.M.S. and Abdel-Aziz A.A.H. (2000). Modulatory effects of melatonin and vitamin E on doxorubicin-induced cardiotoxicity in Ehrlich Ascites Carcinoma-bearing mice. Tumori 86, 157-162.
30. Wakabayashi T., Adachi K., Matsuhashi T., Wozniak M., Antosiewicz J. and Karbowsky M. (1997). Suppression of the formation of megamitochondria by scavengers for free radicals. Mol. Aspects Med. 18, s51-s56.
31. Wakabayashi T. (2002). Megamitochondria formation-physiology and pathology. J. Cell. Mol. Med. 6, 497-538.
32. Wassermann K., Mølgaard K. and Steiness E. (1985). Similar changes in cardiac morphology and DNA synthesis induced by doxorubicin and 4′-epi-doxorubicin. Cancer Chemother. Pharmacol. 15, 244-252.
33. Xu M.F., Ho S., Qian Z.M. and Tang P.L. (2001a). Melatonin protects against cardiac toxicity of doxorubicin in rat. J. Pineal Res. 31,301-307.
34. Xu M.F., Tang P.L., Qian Z.M. and Ashraf M. (2001b). Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci. 68, 889-901.
35. Zeidán Q., Strauss M., Porras N. amd Anselmi G. (2002). Differential long-term subcellular responses in heart and liver to adriamycin stress. Exogenous L-carnitine cardiac and hepatic protection. J. Submicrosc. Cytol. Pathol. 34, 315-321.
36. Zhou S., Starkov A., Froberg M.K., Leino R.L. amd Wallace K.B. (2001). Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res. 61, 771-777.